Natera Inc.

Natera Inc., a biotechnology company headquartered in Austin, Texas, delivers specialized genetic and molecular diagnostic testing services to the Department of Veterans Affairs as a prime contractor across eighteen full-and-open federal awards carrying no set-aside designations. Natera operates exclusively in clinical laboratory reference testing (NAICS 621511, PSC Q301) and competes in the commercial and federal market without SBA certifications or set-aside posture.

Natera's federal portfolio consists entirely of single-award indefinite delivery contracts and related task orders, blanket purchase agreements, and purchase orders issued by VA medical centers and VA Headquarters. The company's capability footprint centers on proprietary cell-free DNA and next-generation sequencing assays for oncology precision medicine: minimal residual disease testing via the Signatera platform (detecting circulating tumor DNA post-treatment to guide therapy decisions), Prospera molecular transplant assessment (noninvasive kidney transplant rejection detection), Renasight kidney disease genetic testing, and Panorama noninvasive prenatal testing, all performed at Natera's CLIA-certified and CAP-accredited reference laboratory. Representative work includes a $6.72 million indefinite delivery contract from VA Headquarters (Sept 2022, ultimate completion Sept 2025) for minimal residual disease testing with issued delivery orders totaling $2.8 million for clinical testing and $496 thousand for research and development; a $550 thousand purchase order from Veterans Integrated Service Network 16 (July 2026, ultimate completion July 2031) covering Renasight, Prospera, and Signatera testing across three specialized assays with five-day turnaround; and a $328.3 thousand purchase order from Veterans Integrated Service Network 17 (Sept 2024, ultimate completion Sept 2029) for tumor whole exome sequencing and peripheral blood circulating tumor DNA testing supporting esophageal cancer research across VA Boston and VA North Texas.

Customer concentration is extreme. The Department of Veterans Affairs Headquarters accounts for 7 awards and $8.7 million in combined potential value (80% of the portfolio), while five distinct Veterans Integrated Service Networks (VISN 10, VISN 19, VISN 16, VISN 6, and VISN 17) collectively hold 11 awards valued at $2.1 million. The portfolio spans 94% award-count coverage across these six customer entities. Natera holds four single-award indefinite delivery contracts (combined potential value $1.2 million) that serve as the primary vehicles for task order issuance, with a September 2026 blanket purchase agreement ($583.5 thousand ceiling through Aug 2031) now anchoring ongoing work for Veterans Integrated Service Network 19. Activity has accelerated in 2025 and 2026 (six awards per year) following lower volume in 2023–2024, though only four awards (combined potential value $361 thousand) face ultimate completion dates within the next twenty-four months, limiting near-term recompete exposure. Natera operates as a 100% prime contractor with no subcontract footprint in the federal space and does not hold seats on government-wide acquisition contracts or multi-agency vehicles.